10-Q: Inhibrx Reports Strong Clinical Wins, Q3 Loss

Inhibrx Biosciences announced positive Phase 2 results for ozekibart in chondrosarcoma, planning a Q2 2026 BLA submission, alongside promising interim data for other pipeline assets, despite reporting a net loss for the nine months ended September 30, 2025.

Summary

• Inhibrx reported a net loss of $107.2 million for the nine months ended September 30, 2025, compared to a net income of $1.7 billion in the prior year period (which included a $2.0 billion gain from the Acquirer transaction).
• Research and development expenses decreased by $82.7 million to $87.7 million for the nine months ended September 30, 2025, primarily due to the spin-off of the INBRX-101 program, termination of INBRX-105, and reduced contract manufacturing and personnel costs.
• General and administrative expenses decreased by $93.5 million to $17.7 million for the nine months ended September 30, 2025, largely due to the absence of $68.1 million in merger-related expenses incurred in the prior year and reduced personnel costs.
• Cash and cash equivalents stood at $153.1 million as of September 30, 2025, with management believing existing cash will fund operations for at least the next 12 months.
• The company secured a new $100.0 million loan agreement with Oxford in January 2025, with an option for an additional $50.0 million, leading to an increase in long-term debt to $99.9 million.
• Ozekibart (INBRX-109) Phase 2 trial for unresectable or metastatic conventional chondrosarcoma met its primary endpoint in October 2025, demonstrating a statistically significant and clinically meaningful median progression-free survival (PFS).
• Ozekibart achieved a 52% reduction in the risk of disease progression or death compared to placebo (Hazard Ratio 0.479; P<0.0001), more than doubling median PFS to 5.52 months versus 2.66 months for placebo in chondrosarcoma.
• Interim results for ozekibart in combination with FOLFIRI for colorectal adenocarcinoma showed a 23% overall response rate (ORR) and 92% disease control rate (DCR) in an expansion cohort.
• Interim results for ozekibart in combination with Irinotecan/Temozolomide for Ewing sarcoma showed a 64% ORR and 92% DCR in an expansion cohort.
• A seamless Phase 2/3 clinical trial was initiated in June 2024 for INBRX-106 in combination with Keytruda as a first-line treatment for head and neck squamous cell carcinoma (HNSCC).
• License fee revenue for the nine months ended September 30, 2025, was $1.3 million from the Scithera License Agreement, compared to $0.1 million from the Regeneron Agreement in the prior year.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the significant clinical success of ozekibart in chondrosarcoma, meeting its primary endpoint in a registrational trial for an unmet medical need, and the planned BLA submission. Promising interim data for other pipeline assets further strengthens the operational outlook. While the company reported a net loss and has an increasing accumulated deficit, this is typical for a clinical-stage biotech, and the recent debt financing provides near-term liquidity. The strategic exploration for monetizing ozekibart also suggests potential for future value creation.

Positives

• Ozekibart (INBRX-109) Phase 2 trial for chondrosarcoma met its primary endpoint, showing a statistically significant and clinically meaningful median PFS, with a 52% reduction in disease progression or death risk compared to placebo.
• Ozekibart is the first investigational therapy to demonstrate a significant PFS benefit in a randomized trial for chondrosarcoma, a disease with no approved systemic options.
• The safety profile of ozekibart was generally well tolerated, with hepatotoxicity risk effectively mitigated by patient exclusion and close monitoring.
• Plans to submit a Biologics License Application (BLA) for ozekibart in chondrosarcoma to the FDA in the second quarter of 2026.
• Promising interim efficacy data for ozekibart in colorectal adenocarcinoma (23% ORR, 92% DCR) and Ewing sarcoma (64% ORR, 92% DCR) expansion cohorts.
• Initiation of a seamless Phase 2/3 clinical trial for INBRX-106 in first-line HNSCC, with initial Phase 2 data expected in Q4 2025.
• Successful securing of a new $100.0 million loan agreement with Oxford, providing additional capital for operations.
• Reduced cash used in operating activities for the nine months ended September 30, 2025, compared to the prior year ($99.7 million vs. $150.7 million).

Negatives

• Reported a significant net loss of $107.2 million for the nine months ended September 30, 2025, compared to a net income in the prior year period.
• Accumulated deficit increased substantially to $213.4 million as of September 30, 2025.
• Total stockholders' equity decreased significantly from $133.6 million at December 31, 2024, to $36.8 million at September 30, 2025.
• The company remains dependent on future capital raises to fund its operations beyond the next 12 months.
• Hepatotoxicity is a known risk for ozekibart's mechanism of action, requiring careful patient selection and monitoring, and one fatal event occurred early in the chondrosarcoma study prior to mitigation measures.

Risks

• Inability to secure adequate additional funding through equity offerings, debt financings, or other capital sources, which could lead to reductions in spending, delays, or elimination of development programs.
• Dilution of existing stockholders' ownership interests if additional capital is raised through public or private equity or convertible debt offerings.
• Potential for restrictive covenants if additional debt financings are pursued, limiting the ability to take specific actions.
• Relinquishing valuable rights to therapeutic candidates, future revenue streams, or research programs on less favorable terms if capital is raised through strategic licensing or collaboration agreements.
• Uncertainty regarding the timing, duration, and completion costs of preclinical studies and clinical trials, and the inherent unpredictability of preclinical and clinical development.
• The process of obtaining marketing approval for therapeutic candidates is costly and uncertain, and there is no guarantee of successful commercialization.
• The emergence and effect of competing or complementary therapeutics or therapeutic candidates could adversely impact market potential.
• Inability to maintain, expand, and defend the scope of the intellectual property portfolio.
• Challenges in attracting and retaining qualified personnel.
• The outcome of efforts to evaluate and potentially pursue alternatives for monetizing ozekibart (INBRX-109) may not result in any transaction, achieve desired objectives, or may distract management and adversely affect business operations.
• Any perceived delay or failure to complete a transaction involving ozekibart could result in negative investor perceptions and a decline in the market price of common stock.

Future Outlook

Inhibrx expects research and development expenses to increase over the next several years as it continues development of therapeutic candidates, especially as they advance into later-stage clinical trials and pre-commercialization activities. The company anticipates incurring significant pre-commercialization expenses and, if approved, commercialization expenses. Future cash needs are planned to be financed through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses, and strategic transactions. The company is also exploring alternatives for monetizing ozekibart (INBRX-109) with a focus on tax efficiency and enhancing stockholder value while minimizing dilution.

Management Comments

• "Ozekibart is the first investigational therapy to demonstrate a significant PFS benefit in a randomized trial for chondrosarcoma, a disease with no approved systemic options."
• "We plan to submit to the FDA a biologics license application in the second quarter of 2026."
• "Based upon our current operating plans, we believe that our existing cash and cash equivalents will be sufficient to fund our operations for at least the next 12 months from the date of filing of this Quarterly Report."
• "We expect to continue to incur net losses for the foreseeable future until, if ever, we have an approved product and can successfully commercialize it."
• "We are exploring a variety of potential alternatives for monetizing ozekibart (INBRX-109), with a focus on tax efficiency and enhancing stockholder value while minimizing dilution."

Industry Context

Inhibrx operates in the highly competitive and rapidly changing biopharmaceutical industry, focusing on novel biologic therapeutic candidates. The positive Phase 2 results for ozekibart in chondrosarcoma are particularly significant as this disease currently lacks approved systemic treatment options, positioning Inhibrx as a potential leader in this unmet medical need. The advancement of INBRX-106 into a seamless Phase 2/3 trial for HNSCC also indicates progress in a competitive oncology landscape, where combination therapies with checkpoint inhibitors like Keytruda are standard. The company's strategy of leveraging proprietary modular protein engineering platforms aims to create superior therapeutic candidates, a common approach in the biotech sector to differentiate from competitors.

Comparison to Industry Standards

• The 52% reduction in the risk of disease progression or death for ozekibart in chondrosarcoma, more than doubling median PFS to 5.52 months versus 2.66 months for placebo, is a strong result, especially given the lack of approved systemic options for this rare cancer. This outcome is highly competitive and potentially transformative for patients, as there are no direct benchmarks for approved systemic therapies in this specific indication.
• The overall response rates (ORR) of 23% in colorectal adenocarcinoma (in combination with FOLFIRI) and 64% in Ewing sarcoma (in combination with IRI/TMZ) for ozekibart are promising for late-line settings. For comparison, typical ORRs in heavily pre-treated metastatic CRC can range from low single digits to around 10-15% for some targeted therapies, making Inhibrx's 23% ORR notable. In Ewing sarcoma, a 64% ORR in a patient population where more than half were third or fourth line is also a strong signal, as response rates in relapsed/refractory settings are often lower.
• The initiation of a seamless Phase 2/3 trial for INBRX-106 in HNSCC (PDL-1 CPS >= 20) in combination with Keytruda aligns with industry trends of developing combination immunotherapies. Keytruda (pembrolizumab) is a leading PD-1 inhibitor, and its use as a backbone for novel agents is common. Success in this trial would position INBRX-106 favorably against other emerging immunotherapies and existing standards of care in HNSCC.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings. It may be involved in legal proceedings or subject to claims incident to the ordinary course of business from time to time.

Related Party Transactions

• The Acquirer (Aventis Inc., a wholly-owned subsidiary of Sanofi S.A.) is identified as a related party following the Merger with the Former Parent.
• The company entered into a Transition Services Agreement with the Former Parent (now Sanofi AATD Inc.) to provide certain transition services for a limited time following the Separation.
• During the second quarter of 2025, the company substantially completed all obligations under the Transition Services Agreement and does not expect any future billings.
• Received payments of approximately $23,000 for previously billed services under the Transition Services Agreement during the nine months ended September 30, 2025, with no remaining receivables from related parties.

Stakeholder Impact

• **Shareholders**: Potential for significant value creation from the successful clinical development of ozekibart and INBRX-106. However, future capital raises may lead to dilution. The exploration of monetizing ozekibart could unlock value but also carries execution risk.
• **Patients**: Positive clinical trial results for ozekibart in chondrosarcoma offer hope for a new treatment option for a disease with no approved systemic therapies. Promising data in CRC and Ewing sarcoma could also lead to new treatments for these patient populations.
• **Employees**: A decrease in headcount was noted in both R&D and G&A, which could impact employee morale or workload. The company's ability to attract and retain qualified personnel is a key risk factor.
• **Creditors**: The company secured a new $100 million loan, increasing its debt obligations. Compliance with covenants under the 2025 Loan Agreement is important for maintaining financial stability.
• **Regulatory Authorities**: The planned BLA submission for ozekibart in Q2 2026 will initiate a significant regulatory review process.

Next Steps

• Submit a Biologics License Application (BLA) for ozekibart (INBRX-109) in chondrosarcoma to the FDA in the second quarter of 2026.
• Continue enrollment and evaluation of the expansion cohort for ozekibart in colorectal adenocarcinoma.
• Continue enrollment and evaluation of the expansion cohort for ozekibart in Ewing sarcoma.
• Provide a more mature dataset update on INBRX-106 in NSCLC (in combination with Keytruda) during the fourth quarter of 2025.
• Announce initial data on the Phase 2 portion of the INBRX-106 seamless Phase 2/3 trial in HNSCC during the fourth quarter of 2025.
• If Phase 2 data for INBRX-106 in HNSCC is positive, ungate the Phase 3 portion of the study, enrolling approximately 350 patients.
• Continue to explore alternatives for monetizing ozekibart (INBRX-109).
• Seek additional capital through equity offerings, debt financings, or other strategic arrangements to fund future operations and development programs.

Key Dates

Recommendation

The filing contains highly positive and price-sensitive news regarding the clinical development of ozekibart (INBRX-109). The successful achievement of the primary endpoint in a registrational Phase 2 trial for chondrosarcoma, a disease with no approved systemic options, is a major de-risking event and a significant catalyst. The planned BLA submission in Q2 2026 indicates a clear path to potential market approval. Additionally, promising interim data for ozekibart in colorectal adenocarcinoma and Ewing sarcoma, along with the advancement of INBRX-106 into a seamless Phase 2/3 trial, demonstrate a robust and progressing pipeline. While the company reported a net loss and has an accumulated deficit, this is typical for a clinical-stage biopharmaceutical company, and the recent $100 million debt financing provides sufficient liquidity for at least the next 12 months. The strategic exploration of monetizing ozekibart further suggests management's focus on maximizing shareholder value. The strong clinical data, particularly for chondrosarcoma, significantly outweighs the current financial losses and positions Inhibrx for substantial future growth and potential value appreciation.

Keywords

Biopharmaceutical, Clinical-stage, Ozekibart, INBRX-109, Chondrosarcoma, Colorectal Cancer, Ewing Sarcoma, DR5 agonist, INBRX-106, OX40 agonist, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Oncology, Clinical Trials, FDA BLA, Drug Development, Biologics, SEC Filing, 10-Q, Financial Results